Phathom Pharmaceuticals annual debt-to-assets ratio
2018
2019
2020
2021
2022
2023
2024
2025
Phathom Pharmaceuticals Debt-to-Assets Ratio Growth & History (PHAT)
Phathom Pharmaceuticals's debt-to-assets ratio was 0.82 for fiscal 2025.
View full Phathom Pharmaceuticals company overviewPhathom Pharmaceuticals annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.82 | 0.28 | +53.14% |
| 2024 | 2024-12-31 | 0.53 | 0.20 | +58.86% |
| 2023 | 2023-12-31 | 0.34 | −0.25 | −42.96% |
| 2022 | 2022-12-31 | 0.59 | 0.11 | +22.15% |
| 2021 | 2021-12-31 | 0.48 | 0.32 | +190.30% |
| 2020 | 2020-12-31 | 0.17 | 0.07 | +81.21% |
| 2019 | 2019-12-31 | 0.09 | −2.07 | −95.76% |
| 2018 | 2018-12-31 | 2.16 | — | — |
Phathom Pharmaceuticals quarterly debt-to-assets ratio
Q4.18
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.51 | −0.31 | −37.93% |
| Q1 2026 | 2026-03-31 | 0.55 | −0.15 | −21.22% |
| Q4 2025 | 2025-12-31 | 0.82 | 0.28 | +53.14% |
| Q3 2025 | 2025-09-30 | 0.87 | 0.42 | +91.57% |
| Q2 2025 | 2025-06-30 | 0.82 | 0.27 | +49.99% |
| Q1 2025 | 2025-03-31 | 0.69 | 0.27 | +64.39% |
| Q4 2024 | 2024-12-31 | 0.53 | 0.20 | +58.86% |
| Q3 2024 | 2024-09-30 | 0.46 | 0.03 | +7.36% |
| Q2 2024 | 2024-06-30 | 0.55 | 0.17 | +46.46% |
| Q1 2024 | 2024-03-31 | 0.42 | −0.26 | −38.34% |
| Q4 2023 | 2023-12-31 | 0.34 | −0.25 | −42.96% |
| Q3 2023 | 2023-09-30 | 0.42 | −0.05 | −10.53% |
| Q2 2023 | 2023-06-30 | 0.37 | −0.07 | −15.30% |
| Q1 2023 | 2023-03-31 | 0.68 | 0.06 | +9.85% |
| Q4 2022 | 2022-12-31 | 0.59 | 0.11 | +22.15% |
| Q3 2022 | 2022-09-30 | 0.47 | 0.08 | +20.31% |
| Q2 2022 | 2022-06-30 | 0.44 | 0.21 | +91.62% |
| Q1 2022 | 2022-03-31 | 0.62 | 0.42 | +210.52% |
| Q4 2021 | 2021-12-31 | 0.48 | 0.32 | +190.30% |
| Q3 2021 | 2021-09-30 | 0.39 | 0.18 | +87.01% |
| Q2 2021 | 2021-06-30 | 0.23 | 0.04 | +20.35% |
| Q1 2021 | 2021-03-31 | 0.20 | 0.02 | +13.16% |
| Q4 2020 | 2020-12-31 | 0.17 | 0.07 | +81.21% |
| Q3 2020 | 2020-09-30 | 0.21 | −0.07 | −25.66% |
| Q2 2020 | 2020-06-30 | 0.19 | — | — |
| Q1 2020 | 2020-03-31 | 0.18 | — | — |
| Q4 2019 | 2019-12-31 | 0.09 | −2.07 | −95.76% |
| Q3 2019 | 2019-09-30 | 0.28 | — | — |
| Q4 2018 | 2018-12-31 | 2.16 | — | — |
Phathom Pharmaceuticals debt-to-assets ratio trends
Over the last five fiscal years, Phathom Pharmaceuticals's debt-to-assets ratio increased from 0.17 to 0.82, a change of 0.65. The latest reported quarter, Q2 2026, shows 0.51.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Phathom Pharmaceuticals source filings ↗Community posts
Phathom’s Voquezna growth narrows its quarterly loss and supports positive operating cash flow
Phathom Pharmaceuticals ($PHAT) reported third-quarter 2026 revenue of $84.7 million, up 71% from a year earlier and 14% from the preceding quarter. Cumulative Voquezna prescriptions surpassed two million, reflecting continued adoption of t ...
Phathom’s Voquezna exclusivity dispute expands with FDA consultation and another challenger
Phathom ($PHAT) said the FDA opened a public docket seeking comment on legal and regulatory questions raised by a challenge to Voquezna’s exclusivity. Comments are due by November 23. Phathom has also moved to intervene in BDR Pharmaceutica ...
